Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. reports developments as a global animal health company serving veterinarians, livestock producers and pet owners. Its updates center on medicines, vaccines, diagnostics, biopharmaceuticals and digital solutions for companion animals and livestock, organized commercially through U.S. and International segments.
Recurring news includes quarterly results and guidance, dividend declarations, investor conference presentations, pipeline and product-regulatory updates, and portfolio activity tied to animal health innovation. Company materials also describe R&D work across areas such as chronic kidney disease, oncology, cardiology, anxiety and obesity, as well as approved long-acting osteoarthritis pain products Lenivia and Portela.
Summary not available.
Summary not available.
Summary not available.
The Zoetis Foundation announced its first round of 2023 grants totaling $5.3 million, supporting 21 initiatives across 15 countries, benefiting livestock farmers and veterinary professionals, and providing earthquake relief in Türkiye. The funding aims to enhance veterinary education, promote diversity, and improve mental well-being in the profession. Notably, the Foundation has committed an additional $100,000 to the American Red Cross for Türkiye earthquake aid. Zoetis Inc. plans to distribute a total of $35 million in grants by the end of 2025, focusing on community and profession support.
Zoetis Inc. (NYSE: ZTS) is set to host a webcast and conference call on May 4, 2023, at 8:30 a.m. (ET) to discuss its first quarter 2023 financial results. CEO Kristin Peck and CFO Wetteny Joseph will present the results and answer questions from financial analysts. Interested investors and the public can access the live webcast through the Zoetis website, and a replay will be available following the event. In 2022, Zoetis generated impressive revenue of $8.1 billion and continues to lead in animal health innovation across over 100 countries.
Summary not available.
Zoetis (NYSE:ZTS) will participate in the TD Cowen Health Care Conference on March 6, 2023. Wetteny Joseph, Executive Vice President and CFO, is set to present at 11:10 a.m. ET and address questions from analysts. A live audio webcast will be available at investor.zoetis.com/events-presentations. Following the event, a replay will be accessible on the Zoetis website. As a leading animal health company, Zoetis focuses on enhancing animal care globally, with $8.1 billion in revenue in 2022 and around 13,800 employees.
Zoetis has secured a $15.3 million grant from the Bill & Melinda Gates Foundation to enhance veterinary care and livestock productivity in Sub-Saharan Africa. This funding will broaden the existing African Livestock Productivity and Health Advancement (A.L.P.H.A.) initiative to include aquaculture and expand into seven new countries, including Ethiopia, Nigeria, Tanzania, Uganda, and Kenya. Over five years, the program aims to train 100,000 stakeholders and improve access to veterinary products, especially for female farmers. This initiative is part of Zoetis' commitment to support sustainable agricultural practices in rapidly developing regions.
Zoetis (NYSE: ZTS) will participate in the Bank of America Securities 2023 Animal Health Summit on March 2, 2023, at 12:30 p.m. ET. The company will be represented by Wetteny Joseph, Executive VP and CFO, who will answer questions from analysts. A live audio webcast will be available for interested parties at investor.zoetis.com/events-presentations. A replay will also be accessible after the event. Zoetis, a leading global animal health company, focuses on advancing animal care and reported revenues of $8.1 billion in 2022.
Zoetis reported its financial results for Q4 and the full year of 2022, achieving a revenue of $2.0 billion for Q4, up 4% year-over-year. The company’s net income for Q4 was $461 million, equating to $0.99 per diluted share. For the full year, Zoetis posted revenues of $8.1 billion, also reflecting a 4% increase, with net income reaching $2.1 billion or $4.49 per diluted share. Looking ahead, Zoetis expects 2023 revenue between $8.575 billion and $8.725 billion, with an operational growth forecast of 6% to 8%. Key growth drivers included companion animal products, although livestock product sales faced challenges from competition and supply issues.